Affordable Access

Publisher Website

Clorgycline delays the phase-position of circadian neurotransmitter receptor rhythms

Authors
Journal
Brain Research
0006-8993
Publisher
Elsevier
Publication Date
Volume
241
Issue
1
Identifiers
DOI: 10.1016/0006-8993(82)91234-3
Keywords
  • Circadian Rhythm
  • Monoamine Oxidase Inhibitor
  • Adrenergic
  • Cholinergic
  • Opiate
  • Dopamine
  • Benzodiazepine Receptors
  • Melatonin
Disciplines
  • Chemistry
  • Medicine

Abstract

Abstract The number of α- and β-adrenergic, muscarinic cholinergic, opiate, and benzodiazepine receptors in rat forebrain, and dopamine and benzodiazepine receptors in striatum, change throughout the day. The diurnal rhythms of these receptors were altered by treatment with the monoamine-oxidase inhibitor clorgyline: following treatment some or all rhythm characteristics of wave form, amplitude, 24-h mean, and phase, were affected. One common effect of treatment was a delay in phase-position of binding to α- and β-adrenergic, opiate and benzodiazepine receptors. Additionally, the nocturnal elevation in pineal melatonin which normally returns to baseline at light onset, persisted 3 h into the light period after clorgyline administratio. These biochemical observations extend bevavioural findings that clorgyline can delay the phase-position of rodent nocturnal activity onset, and does so by slowing the central circadian pacemaker.

There are no comments yet on this publication. Be the first to share your thoughts.